2017 investment and financing report of medical and health industry: 1028 projects raised 157.1 billion yuan, and technological innovation boosted capital growth

Source: arterial network 2018-01-16 according to the statistics of arterial network database, in 2017, the financing scale of global medical and health field increased by 57% compared with 2016, reaching RMB 157.1 billion, a new record The main points of the report are biotechnology and medicine, which promote the growth of financing scale of global medical and health industry; the capital market tends to be rational, which shows that the investment field is more scattered, while the funds are concentrated on high-quality projects; the average amount of single financing has increased significantly, and the average amount of domestic single financing has exceeded 100 million yuan; Compared with the consumption driven service sector, the technology driven medical sector attracts more investment; the domestic Angel round and seed round financing events continue to decrease, and the lack of early rounds in the consumer service sector is more serious; Thanks to the state's support for innovation in the fields of medicine and devices, pharmaceutical, device and biotechnology enterprises with independent innovation strength are likely to receive investment in the future; the number of investment events in the field of grass-roots medicine is reduced, and the industry integration is on the way; Domestic and foreign hot investment fields are similar Compared with overseas, domestic market maturity is lower, and early projects are easier to obtain investment The number of events in the global medical and health industry has decreased, and the project's ability to attract money has greatly improved 2010-2017: the financing scale of the global medical and health industry has changed In 2014, the Research Institute of arterial network eggshell sorted out, and the digital medical wind started, Internet technology has spawned a new medical service mode, and a large number of capital has also started to flow into the medical and health industry The improvement of innovation ability and application demand in the three fields of biotechnology, medical informatization and medical devices has driven the investment growth in the global medical and health field According to the data control of the arterial network, from 2013 to 2015, the total amount of financing in the field of global health care increased by more than three times, 41% of which came from the above three areas In 2016, with the slowdown of investment in medical informatization and medical devices, the growth of the industry's overall financing scale gradually declined However, in 2017, a large number of financing emerged in the fields of biotechnology and medicine, making the scale of financing in the global medical and health industry rise sharply again In 2017, the financing volume increased by 57% year on year, reaching RMB 157.1 billion Compared with 1191 financing events in 2016, there were only 1028 in 2017, down 10% Under the background of the rapid growth of the overall investment scale, the decline of investment events makes the single investment scale rise sharply 2010-2017: the amount of single financing in the global medical and health industry has changed According to the data of the arterial network, the scale of single financing in the global medical and health industry reached 152.88 million yuan in 2017, up 94% compared with 78.8 million yuan in 2016 The trend of capital concentration is obvious The main reasons for the increase of average amount of single financing are that the industry tends to mature, the reduction of early investment, and the emergence of large amount of investment in the fields of medicine and biology 2017: the average amount of financing in the global medical and health industry segments has changed, and the maturity of the sorting industry of the arterial network eggshell Research Institute has improved, making the financing scale of more than half of the segments reached 100 million yuan in 2017 In the pharmaceutical sector with the highest average amount of financing, the average amount of single financing reached RMB 3309.2 billion, double the same period last year 2017: the distribution of financing heat in the subdivisions of the global medical and health industry In 2017, the Research Institute of arterial network eggshell sorted out that there were 391 rounds of global financing, accounting for more than 38% The financing events are mainly concentrated in the four fields of biotechnology, medical equipment, informatization, science and technology and medical treatment driven by technology, with 652 cases in total, accounting for 63.4% of the total However, the service innovation fields driven by consumption demand, such as medical consultation, rehabilitation nursing, maternity and so on, are not ideal in terms of financing due to the gradually clear industrial pattern 2016.2017: financing round migration, arrangement of arterial network eggshell Research Institute Compared with 2016, the round of investment in global medical and health field in 2017 was significantly backward Taking the seed and angel rounds represented by the early investment rounds as examples, 218 financing events occurred in 2016, accounting for 31.6% of the total financing events in that year In 2017, 194 financing events occurred in seed round and angel round, accounting for 18.9% of the total financing rounds Taking the internet medical field as an example, since the rapid development of the new business model in 2014, the industry has become more and more mature, and the moat has been built The capital pays more attention to the enterprises with clear profit model in the later period, and there is little chance for new enterprises Domestic financing scale remained stable, service innovation field became cold, medicine and biotechnology became a new growth point 2010-2017: the financing scale of China's medical and health industry changed, the Research Institute of arterial network eggshell sorted out in 2017, 455 investment events occurred in China, totaling 47.4 billion yuan Compared with the past, in 2017, the growth of financing scale in the field of health care decreased significantly The total is only 1.7 billion yuan more than in 2016 The decline of financing capacity in the large health sector is an important reason for the slowdown in the growth of the industry's financing scale In 2016, the financing scale of the large-scale health sector, which mainly serves health management and sports management, exceeded 6 billion yuan, an increase of more than 100% compared with 2.8 billion yuan in 2015 In 2017, the total amount of financing in this field was only RMB 1.8 billion After the crazy growth from 2013 to 2016, the industry has enough participants, and the product model of the stock market is similar Therefore, new and uncompetitive projects will be difficult to attract investors In the future, in the absence of service model innovation, the reduction of investment enthusiasm will be further intensified with the gradual clarity of the industry pattern On the other hand, compared with 678 financing events in 2016, the number of financing events in China's medical and health industry decreased by a third in 2017, only 455 Similarly, the maturity of service innovation is also the main reason for the decline in the number of overall financing events in the industry 2010-2017: the average amount of financing in China's medical and health industry has changed According to the average amount of single transaction, the average amount of domestic financing is currently lower than the global average The difference of industry maturity makes the financing ability of domestic projects lower than that of overseas projects 2017: the distribution of financing rounds in the medical and health industry between China and the United States The difference in the maturity of sorting out the industry by the Research Institute of arterial network eggshell can be reflected in the distribution of investment rounds Compared with the United States, in the field of health care in China, the number of investment events in rounds a and earlier accounted for 66%, while that in the United States only accounted for 45% This means that compared with the entrepreneurial environment in the United States, the new entrants of China's medical and health industry can rely on their own unique competitive advantages, more easily access to investment opportunities 2015-2017: the distribution of financing rounds in China's medical and health industry Although the maturity of the industry is quite different from that of developed countries, the innovation projects in China's medical and health industry are still maturing Through the analysis of financing rounds, we found that the proportion of seed round and angel round financing in the field of health care in 2017 has more than tripled compared with 2015 In 2017, less than 17% of such rounds took place At the same time, it also means that after two and a half years of development, more mature enterprises have emerged in many areas of the medical and health industry, and the financing capacity of early projects is decreasing 2017: the financing capacity of China's health industry in the subdivision field, the distribution of investment heat in the subdivision field sorted out by the Research Institute of arterial network eggshell, and the financing advantages established by technological innovation have emerged The investment heat of the subdivisional fields with certain technical barriers, such as biotechnology, medical information, medicine and other fields is significantly higher than that of other fields; while the investment heat of service model innovation, such as maternal and infant pregnancy and childbirth, and seeking medical advice, is decreasing For example, there were 47 financing events in 2016 and only 8 investments in 2017 Compared with technology, service innovation has a higher maturity At the same time, the homogenization of products between enterprises is more serious and the replication ability is strong They can grow rapidly through capital injection Once the industry giants are generated, the homogeneous competition environment will be difficult for the smaller players to survive Because of the increasingly clear industry map in the field of service innovation, the early projects that do not have the first mover advantage can no longer attract the attention of investors If we can't break through the existing service paradigm, with the formation of the industry pattern, the investment heat in the field of service innovation may continue to cool down 2017: distribution of financing heat in China's medical and health industry segments, sorted out by arterial network eggshell Research Institute Among the 16 subdivisions of financing, in addition to the small increase in the number of financing events in four subdivisions, the rapid maturity of the industry has led to a decline in financing enthusiasm in other subdivisions, with the decline in medical equipment, big health, medical seeking and other three areas the most In terms of investment rounds, round a transactions are the most frequent, with 207 transactions, accounting for 46% of the total number of events, with a small increase in the proportion compared with 2016 2017: active investment institutions in China's medical and health industry In terms of investment institutions, the Research Institute of arterial network eggshell sorted out more than 10 domestic investment events in 2017, including Jingwei China, Qiming venture capital, Sequoia Capital China and Junlian capital Other more active investment institutions include Softbank China, Honghui capital, gaotejia investment, CCB Lilai Asia Fund and Huagai capital Analysis of large amount events in China: innovation and grass-roots medical fields have the strongest ability to attract gold 2017: the distribution of large amount financing in China's medical and health industry, the a-round financing of Lianying Medical Co., Ltd organized by the Research Institute of arterial network eggshell is 3.333 billion yuan, and the field of medical device innovation ushers in a new era Lianying medical is a provider of high-end medical equipment and medical information solutions, headquartered in Jiading, Shanghai Its business includes R & D and production of high-end medical products in the whole process of image diagnosis and treatment, as well as providing innovative medical information solutions Xue min, chairman of Lianying, said in an open letter to all employees that after financing, Lianying will continue to increase investment in innovation and provide cost-effective products and medical information solutions At present, more than 1700 patent applications have been submitted by Lianying medical, including more than 1500 domestic patent applications and more than 200 international patent applications In 2016, the company won the first gold medal of China Patent in China's high-end medical equipment industry by virtue of the innovative MRI technology "image reconstruction method of plane echo imaging sequence" In May 2017, the world's first panoramic scanning pet CT u explorer explorer explorer explorer of Lianying was officially unveiled The device can realize 4D real-time full body dynamic scanning In recent years, Lianying 96 ring photoconductive PET-CT has entered the hospital of Fujita Health University in Nagoya, Aichi County, Japan, becoming the first high-end medical equipment in the Japanese market in China Adhering to the independence of core technology, taking innovation as the standard and providing competitive independent R & D products are the fundamental reasons for the rapid development of Lianying and its recognition by the capital market At the same time, the largest financing in the field of medical equipment also indicates the rise of domestic innovative equipment.